BioCentury
ARTICLE | Clinical News

MOGN starts Phase II in prostate cancer

April 12, 2001 7:00 AM UTC

MGI Pharma (MOGN) began a European Phase II trial of irofulven acylfulvene in up to 54 patients with hormone refractory prostate cancer. Irofulven is also in a Phase II trial to treat ovarian cancer a...